Biosimilars: Eight Is More Than Enough For FDA
This article was originally published in Pharmaceutical Approvals Monthly
Eight pre-IND and IND applications for biosimilar products have been submitted to the Division of Therapeutic Proteins in CDER's Office of Biotechnology Products, according to division Director Amy Rosenberg.
You may also be interested in...
Several sponsors appear to be taking advantage of the FDA’s biosimilar pathway, even though the agency has yet to clarify how it will handle the applications.
FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.